PMID- 28575464
OWN - NLM
STAT- MEDLINE
DCOM- 20180627
LR  - 20220318
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Print)
IS  - 1522-8517 (Linking)
VI  - 19
IP  - 11
DP  - 2017 Oct 19
TI  - Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in 
      recurrent glioblastoma patients with EGFR amplification.
PG  - 1522-1531
LID - 10.1093/neuonc/nox105 [doi]
AB  - BACKGROUND: We conducted a multicenter, 2-stage, open-label, phase II trial to 
      assess the efficacy and safety of dacomitinib in adult patients with recurrent 
      glioblastoma (GB) and epidermal growth factor receptor gene (EGFR) amplification 
      with or without variant III (EGFRvIII) deletion. METHODS: Patients with first 
      recurrence were enrolled in 2 cohorts. Cohort A included patients with EGFR gene 
      amplification without EGFRvIII mutation. Cohort B included patients with EGFR 
      gene amplification and EGFRvIII mutation. Dacomitinib was administered (45 
      mg/day) until disease progression/unacceptable adverse events (AEs). Primary 
      endpoint was progression-free survival (PFS; RANO criteria) at 6 months (PFS6). 
      RESULTS: Thirty patients in Cohort A and 19 in Cohort B were enrolled. Median age 
      was 59 years (range 39-81), 65.3% were male, and Eastern Cooperative Oncology 
      Group Performance Status 0/1/2 were 10.2%/65.3%/24.5%, respectively. PFS6 was 
      10.6% (Cohort A: 13.3%; Cohort B: 5.9%) with a median PFS of 2.7 months (Cohort 
      A: 2.7 mo; Cohort B: 2.6 mo). Four patients were progression free at 6 months and 
      3 patients were so at 12 months. Median overall survival was 7.4 months (Cohort 
      A: 7.8 mo; Cohort B: 6.7 mo). The best overall response included 1 complete 
      response and 2 partial responses (4.1%). Stable disease was observed in 12 
      patients (24.5%: eight in Cohort A and four in Cohort B). Diarrhea and rash were 
      the most common AEs; 20 (40.8%) patients experienced grade 3-4 drug-related AEs. 
      CONCLUSIONS: Dacomitinib has a limited single-agent activity in recurrent GB with 
      EGFR amplification. The detailed molecular characterization of the 4 patients 
      with response in this trial can be useful to select patients who could benefit 
      from dacomitinib.
CI  - (c) The Author(s) 2017. Published by Oxford University Press on behalf of the 
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com
FAU - Sepulveda-Sanchez, Juan Manuel
AU  - Sepulveda-Sanchez JM
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Vaz, Maria Angeles
AU  - Vaz MA
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Balana, Carmen
AU  - Balana C
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Gil-Gil, Miguel
AU  - Gil-Gil M
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Reynes, Gaspar
AU  - Reynes G
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Gallego, Oscar
AU  - Gallego O
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Martinez-Garcia, Maria
AU  - Martinez-Garcia M
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Vicente, Elena
AU  - Vicente E
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Quindos, Maria
AU  - Quindos M
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Luque, Raquel
AU  - Luque R
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Ramos, Ana
AU  - Ramos A
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Ruano, Yolanda
AU  - Ruano Y
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Perez-Segura, Pedro
AU  - Perez-Segura P
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Benavides, Manuel
AU  - Benavides M
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Sanchez-Gomez, Pilar
AU  - Sanchez-Gomez P
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
FAU - Hernandez-Lain, Aurelio
AU  - Hernandez-Lain A
AD  - Neuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical 
      Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; Medical Oncology, 
      Institut Catala d'Oncologia, Badalona, Spain; Medical Oncology, Institut Catala 
      d'Oncologia, IDIBELL, L'Hospitalet, Barcelona, Spain; Medical Oncology, Hospital 
      Universitari I Politecnic La Fe, Valencia, Spain; Medical Oncology, Hospital 
      Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain; Medical 
      Oncology, Hospital del Mar, Barcelona, Spain; Medical Oncology, Hospital 
      Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; Medical 
      Oncology, Hospital A Coruna, A Coruna, Spain; Medical Oncology, Complejo 
      Hospitalario de Granada, Granada, Spain; Neuro-radiology, Hospital Universitario 
      12 de Octubre, Madrid, Spain; Molecular Pathology Unit, Hospital Universitario 12 
      de Octubre, Madrid, Spain; Medical Oncology, Hospital Clinico de San Carlos, 
      Madrid, Spain; Medical Oncology, Hospital Universitario Regional y Virgen de la 
      Victoria, Malaga, Spain; Neuro-oncology Unit, Instituto de Salud Carlos III, 
      Majadahonda, Madrid, Spain; Neuro-pathology, Hospital Universitario 12 de 
      Octubre, Madrid, Spain.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Quinazolinones)
RN  - 0 (epidermal growth factor receptor VIII)
RN  - 5092U85G58 (dacomitinib)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*drug therapy/genetics/pathology
MH  - ErbB Receptors/*antagonists & inhibitors/genetics
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Amplification
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Glioblastoma/*drug therapy/genetics/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Prognosis
MH  - Quinazolinones/*therapeutic use
MH  - Signal Transduction
MH  - Survival Rate
PMC - PMC5737732
OTO - NOTNLM
OT  - EGFR
OT  - dacomitinib
OT  - glioblastoma
OT  - high-grade glioma
EDAT- 2017/06/03 06:00
MHDA- 2018/06/28 06:00
PMCR- 2018/10/01
CRDT- 2017/06/03 06:00
PHST- 2017/06/03 06:00 [pubmed]
PHST- 2018/06/28 06:00 [medline]
PHST- 2017/06/03 06:00 [entrez]
PHST- 2018/10/01 00:00 [pmc-release]
AID - 3860167 [pii]
AID - nox105 [pii]
AID - 10.1093/neuonc/nox105 [doi]
PST - ppublish
SO  - Neuro Oncol. 2017 Oct 19;19(11):1522-1531. doi: 10.1093/neuonc/nox105.